Skip to contentA
Acro Biomedical Co., Ltd.
A
ACBMAcro Biomedical Co., Ltd. Q2 2020 · 10-Q
Revenue$0.00$0.00— vs Q2 2019 Net Income-$63.70K-$63.70KN/M vs Q2 2019 EPS Diluted$0.00$0.00— vs Q2 2019 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
-$62,771
N/M
Operating Cash Flowderived-$71,831N/M ended Jun 30, 2020 · filed Aug 19, 2020 · 50 d after period end